April 25, 2017 / 5:51 AM / 3 months ago

BRIEF-Transgene and Bristol-Myers Squibb announce clinical research collaboration

1 Min Read

April 25 (Reuters) - Transgene Sa:

* Co and Bristol-Myers Squibb announce clinical research collaboration to evaluate TG4010 with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer

* Phase 2 clinical trial will explore potential of combining Transgene's TG4010, in conjunction with Bristol-Myers Squibb's immune checkpoint inhibitor, Opdivo

* Under terms of agreement, Transgene will be sponsor of trial. Bristol-Myers Squibb will provide Opdivo for use in study. Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below